Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3164054 | 0.84 | HIF1A (0.69) | HIF1AHSD17B10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3184095 | 0.83 | HIF1A (0.62) | HIF1AHSD17B10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6843822 | 0.83 | SLC6A3 (0.63) | HIF1AHSD17B10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3172811 | 0.83 | HIF1A (0.62) | HIF1AHSD17B10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11408759 | 0.83 | SLC6A2 (0.69) | HIF1AHSD17B10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3164269 | 0.83 | HIF1A (0.62) | HIF1AHSD17B10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1533285 | 0.82 | SLC6A3 (0.62) | HIF1AHSD17B10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1794707 | 0.82 | SLC6A3 (0.62) | HIF1AHSD17B10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1794708 | 0.82 | SLC6A3 (0.62) | HIF1AHSD17B10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4776066 | 0.81 | HIF1A (0.60) | HIF1AHSD17B10SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016357-A1 | Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain | SOSEI R & D LTD. (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-1993544-A1 | THE USE OF BETA-AMINOALCOHOLS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | Sosei R&D Ltd. (GB) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102011-A1 | THE USE OF BETA-AMINOALCOHOLS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016357-A1 | Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain | HRH3, HRH2, HRH1 | HIF1A 709/4885HSD17B10 566/4885SLC6A2 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.